Publications

Munger MA, Van Tassell, B, Lafleur J. Medication noncompliance: An unrecognized cardiovascular risk factor.Medscape General Medicine 2007;http://medgenmed.medscape.com/medgenmed

Munger MA. New agents for managing hyponatremia in hospitaized patients. Am J Healh Syst Pharm 2007;64: 253-65.

Munger MA, Ng TMH, Van Tassell B. Controversy and conflict in the treatment of acute decompensated heart failure. Nesiritide is an evidenced based treatment. Pharmacother 2007;27(5):619-25.

Van Tassell B, Munger MA. Aliskiren: A promising new agent for the treatment of hypertension. Ann Pharmacother 2007;41(2): 1345.

Drummond W, Munger MA, Essop MR, Maboudian M, Khan M, Keefe DL Antihypertensive efficacy of the oral renin inhibitor aliskiren as addm therapy in patients not responding to amlodipine. Am J Hypertens 2007;9(10):742-50..

Munger MA. Management of acute da:ompensated heart failure: Treatment, controversy, and future directions. Pharmacotherapy 2006;26: (8 pt 2): 131 S-8S.

Howard PA, Cheng, JWM, Crouch MA, Colucci V J, Kalus JS, Spliner SA,Munger MA. Drug therapy recommendations from the 2005 ACC/ AHA Guidelines for treatment of chronic heart failure. Ann Pharmacother 2006;: Published Online, 8 August 2006, www.theannals.com. DOl 10. 1345/aph. IH059.

Atherton A, Munger MA. Importance of Professionalism and Patient Advocacy. West J Pharmaceut Care 2005;1(1):27-28.

Munger MA, Stillman J, Botkin JR The keystone of human subject's protections: The Institutional Review Board. Utah Health: An Annual Review. 2005; Volume X(#I): 8-11.

Ng TMH, Carter 0, GuilloryGS, Howard PA, Lee CR, Rodgers JE, Uber PA, Wiggins BS, Munger MA, Patterson, JH. High impact articles related to the pharmacotherapeutic management of systolic heart failure Pharmacotherapy 2004;24(11) 1594-633.

Munger MA, Hawkins D. Atherothrombosis: Epidemiology, Pathophysiology, and Prevention J Am Pharm Ass. 2004;44(2 Suppl 1)S5-S12.

Munger MA, Carter O. Epidemiology and practice patterns of acute decompensated heart failure. Am J Health-Syst Pharm 2003;60(SuppI4):S4-15

Munger MA. Acute decompensated heart failure: Rethinking the economics in treatment. Introduction. Am J Health-Syst Pharm. 2003;60(SuppI4):Sl-S3.

Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber JA, Williams G, Wittes J, Zanchetti A, Anders RJ, (Munger MA), Principal results of the controlled onset verapamil inivestigation of cardiovascular end points (CONVINCE) trial. JAMA 2003;289:2073-2082.

Carter O, Nathisuwan S, Munger MA. An analysis of retention and turnover rates among academic pharmacy departments over five years. Ann Pharmacother 2003;37:197-201.

deLissovoy, G, Stier DM, Ciesla G, Horton DP, Munger M, Burger AJ. Economic implications of nesiritide versus dobuamine in the treatment of acute decompensated heart failure. Am Heart J 2003;92(5)631-3.

Ng TMH, Munger MA, Lombardi WL, Doing TH, Young DC, Ryujin DT, Stanek EJ. Are chronic inhaled β-agonists beneficial and safe in heart failure? J Cardiovasc Pharmacol 2002;Jul;40(1):140-145.

Ng TMH, Cheang KI, Munger MA, Callahan KS. Neurohormonal activation does not explain elevated monocyte tissue factor expression in heart failure. Thrombo Haemost 2002;87:176-7.

Gallagher J, Fisher C, Sherman B, Munger M, Meyers B, Ellison T, Fischkoff S, Barchuk WT, Teoh L, Velagapudi R. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNFa antibody afelimomab in patients with sepsis syndrome. Intensive Care Med 2001;27(7):1169-78.

Bakris G, Gradman A, Reif M, Wofford M, Munger M, Haris S, Vendetti J, Michelson E, Wang R, and CLAIM Study 231 Investigators. A forced-titration study of antihypertensive efficacy of candesartan cilexetil in compaison to losartan-CLAIM Study I. J Clin Hyper 2001:3(1):16-21.

Munger MA, Ateshkadi A, Flaharty KK, Marshall EH, Cheung AK. Cardiopulmonary events during hemodialysis using various membranes and dialysate buffers. Am J Kid Dis 2000;36:130-9.

Young MB, Stilling WJ, Munger MA. Pharmacy practice acts: A decade of progress. Ann Pharmacother 1999;33:920-6.

Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T, Munger M, Metzler M, Zaloga G, Murray M, Lowry S, Conger J, McKeown W, O'shea M, Baughman R, Wood K, Haupt M, Kaiser R, Simms H, Warnock D, Summer W, Haenftling K, Capra W, Pike M, Guler H-P. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999;55:2223-32.

Zuschke CA, Keys I, Munger M, Carr A, Marinides G, Flanagan TL, Cushing DJ, Layes JL, Michelson EL, on behalf of the Candesartan Cilexetil Study Investigators. Comparison of candesartan cilexetil administered once versus twice daily for treatment of systemic hypertension. Clin Ther 1999;21:464-74.

Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, Wolf RA. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999;33:1174-1181.

Moser LR, Callahan KS, Cheung AK, Stoddard GJ, Munger MA ACE inhibitor effects on platelet dynamics in stage I-II hypertension. J Cardiovasc Pharmacol 1997;30(3):461-7.

Bednarczyk EM, Furniss SM, Green JA, Nara AR, Munger MA. Evaluation of the indomethacin-nitroglycerin interaction using positron emission tomography. J Cardiovasc Pharmacol 1997;30(3):731-3.

Sherman BW, Munger MA, Foulke G, Rutherford WF, Panacek EA. High-dose epinephrine treatment for cardiac arrest following failure of standard therapy. Pharmacother. 1997;17(2):242-7.

Gottlieb SS, Singh S, Munger MA, Eichhorn EJ, Ilgenfritz J, Hanyok J. The hemodynamic actions of the class III antiarrhythmic agent, d-Sotalol, in patients with congestive heart failure. Am J Cardiol 1996;78:1411-15.

Ateshkadi A, Munger MA. Pharmacy practice scientific publication rate. Pharmacother 1996;16:1128-32.

Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of pro-inflammatory cytokines in patients with mild to moderate heart failure. Am J Cardiol 1996;77:723-7.

Grunden JW, Gilbert EM, Munger MA,. Augmented digoxin concentrations with carvedilol dosing in moderate heart failure. Am J Therapeut 1994;1:157-164.

Munger MA, Botti RE, Kasmer RJ, Grinblatt MA. Effect of fructose-1,6-diphosphate on myocardial contractility in patients with left ventricular dysfunction. Pharmacother 1994;14(5):522-528.

Stanek EJ, Nara AR, Stroll K, Nair RN, Decker MJ, Munger MA. Effect of angiotensin converting enzyme inhibitor therapy on arterial oxygen saturation in patients with mild to moderate heart failure. Pharmacother 1994;14(3):321-329.

Munger MA, Stanek, EJ, Nara AR, Stroll KP, Decker MJ, Nair RN. Abnormal arterial oxygenation in chronic heart failure. Am J Cardiol 1994;73:180-185.

Munger MA, Nara AR:eurohormonal activation does not e, Pospisil RA, Stoddard GJ, Schleman M. Invasive pharmacodynamic characterization of combined ibopamine and calcium antagonist therapy in congestive heart failure. Pharmacother 1993;13(3):218-223.

Munger MA, Stilling BJ, Gardner SF. Pharmacy Practice Acts: A five-year follow-up. Ann Pharmacother 1993;27(5):560-565.

Munger MA, Chance M, Nair RN, Prescott AW, Nara AR, Simonson MS, Green JA, Posvar EL. Evaluation of regional blood flow and cardiac contractility of quinapril HCl in a congestive heart failure population. J Clin Pharm. 1992;32:70-76.

Gardner SF, Stanek EJ, Munger MA. Medical versus pharmaceutical continuing education: Are both appropriate for pharmacists? Drug Intel Clin Pharm. 1991;25:1336-1338.

Bednarczyk EM, Panacek EA, Leisure G, Munger MA, Miraldi F, Rutherford WF, Green JA. Hyperventilation-induced reduction in cerebral blood flow: Assessment by positron emission tomography. Drug Intel Clin Pharm. 1990;24:456-460.

Munger MA, Rutherford WF, Hakki AHI, Gonzalez FM, Bednarczyk EM, Glynn G, Weed SG, Panacek EA, Green JA. Assessment of fenoldopam mesylate in severe systemic hypertension. Crit Care Med. 1990;18:502-504.

Munger MA, Benotti J, Green JA, Jarvis RC, Nara AR, Pospisil RA, Kasmer RJ. Assessment of hemodynamic tolerance from a 24-hour, intravenous infusion of fenoldopam mesylate in congestive heart failure. Am J Cardiol. 1990;60:206-210/Cardiology Digest 1990;7:27-28.

Kasmer RJ, Cutler RE, Munger MA, Jarvis RC, Hricik D, Pospisil R, Nara AR, Green JA. Effects of Ibopamine HCl on renal failure in patients with congestive heart failure. Brit J Pharmacal. 1990;30:485-489.

Rutherford WF, Panacek EA, Griffith K, Green JA, Munger MA, Bednarczyk EM, Miraldi F, Fisher CJ. Prediction of changing cerebral blood flow by use of the conjunctival oxygen tension/arterial oxygen tension index. Crit Care Med. 1989;17:1328-1332.

Bednarczyk EM, White WB, Munger MA, Gonzalez FM, Panacek EA, Weed SG, Rutherford WG, Nara AF, Green JA. Comparative acute blood pressure reduction from intravenous fenoldopam mesylate vs. sodium nitroprusside in patients with severe hypertension. Am J Cardiol. 1989;63:993-996.

Munger MA, Jarvis RC, Nair RN, Kasmer RJ, Nara AR, Urbancic A, Green JA. Elucidation of the nifedipine-quinidine interaction. Clin Pharmacal Ther. 1989;45:411-416.

Munger MA, Green JA, Greve PA, Lovejoy LS. Professional liability for pharmacists: A focus on pharmacy practice acts. Drug Intel Cain Pharm. 1988;22:886-888.

Klamerus KJ, Munger MA. The impact of clinical pharmacy services on digoxin serum concentration monitoring. Am J Hosp Pharm. 1988;45:1887-1893.

Botkin JA, Munger MA, Shea P, Coffin C, Mineau G, and the Ad Hoc Tissue Advisory Committee. Management of human tissue resources for research in academic medical centers: Points to consider. JAMA 2002;:(Submitted for publication).

Botkin JA, Clayton E, Nelson R, Wilfond B, Munger MA. Letter to the Editor. Lazerus et al. Long-acting β2-agonist monotherapy versus continued therapy with inhaled corticosteroids in patients with persistent asthma. JAMA 2001;286:3075-6.

Spinler SA, Hilleman D, Cheng JWM, Howard P, Maura VF, Lopez L, Munger M, Gardner S, Nappi J. New recommendations from the 1999 American College of Cardiology/American Heart Association Acute Myocardial Infarction Guidelines. Ann Pharmacother 2001;35:589-617.

Munger MA, Cheang KI. β-Blocker Therapy: A standard of care for heart failure. Pharmacotherapy 2000;20:(11 pt 2):359S-367S.

Munger MA, Steinberg I, Reif M, Papademetriou. Improving therapeutic choices in the management of hypertension. Drug Benefit Trends 2000;12(Suppl E):5:eurohormonal activation does not e-10 Ng TMH, Kenney JK, Munger MA. Growth Hormone: A promising treatment for the failing heart? Pharmacotherapy 2000;20:1096-1106.

Munger MA. Critical overview of antihypertensive therapies: What is preventing us from getting there? Am J Manag Care 2000;6:S211-S221.

Bayat M, Davis L, Knoell D, Korth-Bradley J, Munger M, Shaefer M, Vlasses P, Werming D, Ujhelyi M. The clinical pharmacist as principal investigator. Pharmamcother 2000;20:599-608.

Munger MA, Kenney JK. A chronobiologic approach to the pharmacotherapy of hypertension and angina. Ann Pharmacother 2000;34(11):1313-19.

Sommerville KT, Lombardi WL, Munger MA, Taylor DO. The role of HMG-CoA Reductase Inhibitors after cardiac transplantation. Pharmacother 2000;:(In Press).

Ng TMH, Kenney JK, Munger MA. A clinical approach to heart failure. Drug Topics 1998;Oct:27S-30S.

Bleske B, Gilbert EM, Munger MA. Carvedilol: Therapeutic Application and Practice Guidelines. Pharmacother 1998;18:729-37.

Munger MA, Furniss SM. Is there an expanded role for digoxin in heart failure and sinus rhythm? An antagonist viewpoint. Ann Pharmacother 1997;31:893-6.

Hilleman DE, Lopez LM, Munger MA, Nolan PE, Patterson JH, Tisdale JE. ASHP Therapeutic Guidelines on Angiotensin-Converting-Enzyme Inhibitors in Patients with Left Ventricular Dysfunction. Am J Health-Systems Pharm 1997;54:299-313/Congestive Heart Failure 1998;4:29-43.

Furniss SM, Munger MA. Use of positive inotropes in advanced cardiac life support. Anesth Today 1996;7(1):1-5 [INVITED MANUSCRIPT]

Munger MA, Furniss SM. Angiotensin II receptor blockers: Novel therapy for heart failure? Pharmacother 1996;16:59S-68S.

Moser LR, Panacek EA, Munger MA. Intravenous diltiazem for acute ventricular rate control: A case report of a fatal complication. Pharmacother 1996;16:306-10.

Kelsey JJ, Moser LR, Jennings JC, Munger MA. Presence of azithromycin breast milk concentrations: A post-partum case report. J Obstr Gynecol 1994;170:1375-6.

Beckwith C, Munger MA. Effect of angiotensin converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother. 1993;27(6):755-766./Clinical Abstracts/Current Therapeutic Findings 1993;12:40.

Munger MA. Angiotensin-converting enzyme inhibitor functional changes on renal pathophysiology in congestive heart failure. Ann Pharmacother. 1993;27(2):205-210/Clinical Abstracts/Current Therapeutic Findings 1993;12:8.

Panacek EA, Munger MA, Rutherford WF, Gardner SF. Nitropatch electrical conduction: Case Reports. Am J Emerg Med. 1992;10:128-129.

Gardner SF, Stanek EJ, Munger MA. Medical versus pharmaceutical continuing education. (Author's reply). Ann Pharmacother. 1992;26:844.

Gardner SF, Rutherford WF, Munger MA, Panacek EA. Drug-induced supraventricular tachycardia: A case report of fluoxetine. Ann Emerg Med. 1991;20:194-197.

Munger MA, Stanek EJ, Panacek EA. A novel dopaminergic agent for severe systemic hypertension: Focus on fenoldopam mesylate. Hospital Formul. 1991;26:453-460.[INVITED MANUSCRIPT]

Stanek EJ, Nair RN, Munger MA. Letter to the Editor: Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormality. Am Heart J. 1991;121(6):1849-1850.

Munger MA, Gardner SF, Jarvis RC. Endocrinologic warfare: The role of angiotensin-converting enzyme inhibitors in congestive heart failure. J Pharm Pract. 1990;3(5):318-331.

Munger MA, Forrence EA. Anistreplase: A new thrombolytic for the treatment of acute myocardial infarction. Clin Pharm. 1990;9:530-540/Amer J Hosp Pharm. 1990;47:1886-1887 [INVITED MANUSCRIPT]

Green JA, Munger MA. Discrepancy between pharmacist training, the futuristic practice of pharmacy and the pharmacy practice acts. The Ohio Pharmacist. 1989;38(9):20-22. Green JA,Munger MA, Reed RC, Bednarczyk EM. Pharmacy practice Acts: Are they stifling professional growth? Amer Pharm. 1989;NS29(12):20-22.

Green JA, Munger MA. On the fringes. Pharmacother. 1989;9(2):95-98

Munger MA, Effron BA. Amoxapine cardiotoxicity. Ann Emerg Med. 1988;17(3):274-278.

Schuler ME, Goldman MA, Munger MA. The role of calcium channel blockers in migraine prophylaxis. Drug Intel Clin Pharm. 1988;22(3):187-191.

Green JA, Munger MA. Why are clinical pharmacy services considered "dispensable." (Letter) Am J Hosp Pharm. 1987;44:499-504.

Munger MA, Green JA. The practitioner/director. (Commentary) Amer J Hosp Pharm. 1987;44:592-593.

Munger MA, Green JA. Pharmacy directors need vision, not advanced clinical training. (Author's reply) Amer J Hosp Pharm. 1987;44:1777.

Munger MA. Parenteral nutrition: A time for interdisciplinary cooperation. JPEN 1987;11(6):599.

Klamerus KJ, Munger MA. Establishment of guidelines for cardioplegia composition. Am J Hosp Pharm. 1986;43:1279-1482.

Stanek EJ, Munger MA. Heart Failure: In Pharmacotherapy Self Assessment Program. American College of Clinical Pharmacy, Kansas City, Missouri, 1997, Module 1, Book A:73-104.

Munger MA, Stanek EJ, Moser LM. Heart Failure. In: Pharmacotherapy Self Assessment Program. American College of Clinical Pharmacy, Kansas City, Missouri, 1995, Module 1, Book A:151-180.

Munger MA, Stanek EJ. Heart Failure. In: Pharmacotherapy Self Assessment Program. American College of Clinical Pharmacy, Kansas City, Missouri, 1991, Module 1, Book A:85-97.

Go To...

• Profile
• Publications
• Courses Taught